Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of dapagliflozin on coronary macrovascular and microvascular function in type 2 diabetes (DAPAMICRO)
2021-003310-39Phase 4Terminated
- Sponsor
- Saint-Pierre University Hospital
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of dapagliflozin in type 2 diabetes mellitus (T2DM), coronary arteriosclerosis and acute coronary syndrome (ACS) (2 arms), sponsored by Saint-Pierre University Hospital. Primary endpoint: Change in coronary flow reserve, fractional flow reserve, and index of microcirculatory resistance. Started Jul 2021; status: terminated.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)coronary arteriosclerosisacute coronary syndrome (ACS)
Beyond the preview
Go deeper on 2021-003310-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003310-39.